MedTrace Logo

Expanded Access to Ziftomenib

NCT05738538 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-06-04

No results posted yet for this study

Summary

Requests for single patient expanded access to ziftomenib monotherapy may be considered for eligible adult patients with Acute Lymphoblastic Leukemia (ALL) with KMT2A rearrangements, or Acute Myeloid Leukemia (AML), with NPM1 mutations or KMT2A rearrangements.

To request access, use Responsible Party contact information provided in this record.

Expanded access for ziftomenib is only available in the United States.

Conditions

  • Acute Lymphoblastic Leukemia, With Appropriate Mutations
  • Acute Myeloid Leukemia, With NPM1 Mutations

Interventions

DRUG

ziftomenib

Sponsors & Collaborators

  • Kura Oncology, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05738538 on ClinicalTrials.gov